Ignite Creation Date:
2025-12-24 @ 5:04 PM
Ignite Modification Date:
2025-12-26 @ 8:06 AM
Study NCT ID:
NCT00170950
Status:
TERMINATED
Last Update Posted:
2023-10-24
First Post:
2005-09-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension
Sponsor:
Novartis
Organization:
Study Overview
Official Title:
A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension
Status:
TERMINATED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ACCOMPLISH
Brief Summary:
A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to evaluate the effectiveness of the combination on reducing heart disease and death in a high risk hypertensive population.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: